MedTrace Logo

Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma

NCT05117814 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-08-03

No results posted yet for this study

Summary

Zanubrutinib is a novel BTK inhibitor with proven activity in patients with various B-cell lymphomas addicted to the B-cell receptor signaling pathway.

Conditions

  • CNS Lymphoma

Interventions

DRUG

Zanubrutinib

as long as 24 months or consolidated with ASCT or WBRT after achieving PR or CR

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Shenmiao Yang, MD · Peking University Peoples' Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2023-01-31
Completion
2025-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05117814 on ClinicalTrials.gov